A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.

@article{Taplin2008API,
  title={A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.},
  author={M E Taplin and Judith B. Manola and William K Oh and Philip W. Kantoff and Glenn J. Bubley and Matthew Raymond Smith and Diana Barb and Christos Socrates Mantzoros and Edward P. Gelmann and Steven P. Balk},
  journal={BJU international},
  year={2008},
  volume={101 9},
  pages={1084-9}
}
OBJECTIVE To evaluate mifepristone (RU-486) in patients with castration-resistant prostate cancer (CRPC), with a correlative assessment of serum androgens and androgen metabolites PATIENTS AND METHODS The androgen receptor (AR) is critical in the development and progression of prostate cancer, but available antiandrogens incompletely abrogate AR signalling. Mifepristone is a potent AR antagonist that functions by competing with androgen, preventing AR coactivator binding and by enhancing… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Similar Papers

Loading similar papers…